Advanced TNBC patients often have rapid tumor progression, show resistance to multiple therapies, and associate with lower survival rates.[19] While both RT and ICT show promising improvement of local disease control and prolong survival, only a small proportion of TNBC patients can benefit from ICT due to the immunosuppressive TME.[20] Previous studies have demonstrated that RT can induce ICD, activate TME and increase PD‐L1 expression in tumors, thus improving the antitumor effect of ICT.[21] Hence, it is rational to activate the immune response, thereby enhancing the efficacy of ICT. Here, CD274 is linked to neoplasm.